Roche/Ipsen's Suspended Taspoglutide Could Be Another Diabetes Casualty
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche's decision to halt dosing in a trial of the GLP-1 receptor agonist taspoglutide following an announcement of a major development delay illustrates the intensively competitive nature of the diabetes market